

Journal of Medical Devices Journal

Copy of e-mail Notification

Journal of Medical Devices Published by ASME

Dear Author,

Congratulations on having your paper accepted for publication in the ASME Journal Program.

Your page proof is available in PDF format from the ASME Proof Download & Corrections site here:

<http://115.111.50.156/jw/AuthorProofLogin.aspx?pwd=23591195602e>

Login: your e-mail address

Password: 23591195602e

Please keep this email in case you need to refer back to it in the future.

You will need Adobe Acrobat Reader software to view the file. This is free software and a download link is provided when you log in to view your proofs.

Responsibility of detecting errors rests with the author. Please review the page proofs carefully and:

- 1) Answer any queries on the first page "Author Query Form"
- 2) Proofread any tables and equations carefully
- 3) Check to see that any special characters have translated correctly

RETURNING CORRECTIONS:

To return corrections, please use the ASME Proof Download & Corrections Submission Site (link above) and provide either:

1. Annotated PDF
2. Text entry of corrections, with line numbers, in the text box provided

Additional files, as necessary, can also be uploaded through the site.

SPECIAL NOTES:

Your Login and Password are valid for a limited time. Please reply within 48 hours. Your prompt attention to and return of page proofs will speed the publication of your work.

For all correspondence, please include your article no. (MED-12-1079) in the subject line.

This e-proof is to be used only for the purpose of returning corrections to the publisher.

If you have any questions, please contact: asme.cenveo@cenveo.com.

Sincerely,

Mary O'Brien, Journal Production Manager

STATEMENT OF EDITORIAL POLICY AND PRACTICE

The Technical Committee on Publications and Communications (TCPC) of ASME aims to maintain a high degree of technical, literary, and typographical excellence in its publications. Primary consideration in conducting the publications is therefore given to the interests of the reader and to safeguarding the prestige of the Society.

To this end the TCPC confidently expects that sponsor groups will subject every paper recommended by them for publication to careful and critical review for the purpose of eliminating and correcting errors and suggesting ways in which the paper may be improved as to clarity and conciseness of expression, accuracy of statement, and omission of unnecessary and irrelevant material. The primary responsibility for the technical quality of the papers rests with the sponsor groups.

In approving a paper for publication, however, the TCPC reserves the right to submit it for further review to competent critics of its own choosing if it feels that this additional precaution is desirable. The TCPC also reserves the right to request revision or condensation of a paper by the author or by the staff for approval by the author. It reserves the right, and charges the editorial staff, to eliminate or modify statements in the paper that appear to be not in good taste and hence likely to offend readers (such as obvious advertising of commercial ventures and products, comments on the intentions, character, or acts of persons and organizations that may be construed as offensive or libelous), and to suggest to authors rephrasing of sentences where this will be in the interest of clarity. Such rephrasing is kept to a minimum.

Inasmuch as specific criteria for the judging of individual cases cannot, in the opinion of the TCPC, be set up in any but the most general rules, the TCPC relies upon the editorial staff to exercise its judgment in making changes in manuscripts, in rearranging and condensing papers, and in making suggestions to authors. The TCPC realizes that the opinions of author and editor may sometimes differ, and hence it is an invariable practice that no paper is published until it has been passed on by the author. For this purpose page proofs of the edited paper are sent to the author prior to publication in a journal. Changes in content and form made in the proofs by authors are followed by the editor except in cases in which the Society's standard spelling and abbreviation forms are affected.

If important differences of opinion arise between author and editor, the points at issue are discussed in correspondence or interview, and if a solution satisfactory to both author and editor is not reached, the matter is laid before the TCPC for adjustment.

Technical Committee on Publications and Communications (TCPC)
Reviewed: 05/2012

Connor Randall

Daniel Bridges

Department of Physics,
University of California,
Santa Barbara, CA 93106

Roberto Guerri

Xavier Nagues

Lluís Puig

Elisa Torres

Leonardo Mellibovsky

Hospital del Mar-IMIM-Universitat
Autònoma and RETICEF,
Instituto Carlos III,
Barcelona, 08003 Spain

Kevin Hoffseth

Department of Physics,
University of California,
Santa Barbara, CA 93106

Tyler Stalbaum

Ananya Srikanth

Materials Engineering,
Purdue University,
West Lafayette, IN 47907

James C. Weaver

Wyss Institute for Biologically
Inspired Engineering,
Harvard University,
Cambridge, MA 02138

Sasha Rosen

Heather Barnard

Department of Physics,
University of California,
Santa Barbara, CA 93106

Davis Brimer

Alex Proctor

James Candy

Active Life Technologies LLC,
Santa Barbara, CA 93101

Christopher Saldana

Srinivasan Chandrasekar

Materials Engineering,
Purdue University,
West Lafayette, IN 47907

Timothy Lescun

Veterinary Clinical Sciences,
Purdue University,
West Lafayette, IN 47907

Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength

A novel, hand-held Reference Point Indentation (RPI) instrument, measures how well the bone of living patients and large animals resists indentation. The results presented here are reported in terms of Bone Material Strength, which is a normalized measure of how well the bone resists indentation, and is inversely related to the indentation distance into the bone. We present examples of the instrument's use in: (1) laboratory experiments on bone, including experiments through a layer of soft tissue, (2) three human clinical trials, two ongoing in Barcelona and at the Mayo Clinic, and one completed in Portland, OR, and (3) two ongoing horse clinical trials, one at Purdue University and another at Alamo Pintado Stables in California. The instrument is capable of measuring consistent values when testing through soft tissue such as skin and periosteum, and does so handheld, an improvement over previous Reference Point Indentation instruments. Measurements conducted on horses showed reproducible results when testing the horse through tissue or on bare bone. In the human clinical trials, reasonable and consistent values were obtained, suggesting the Osteoprobe® is capable of measuring Bone Material Strength in vivo, but larger studies are needed to determine the efficacy of the instrument's use in medical diagnosis. [DOI: 10.1115/1.4024829]

Keywords: bone, bone fracture, bone mechanical properties, bone material properties

Manuscript received June 13, 2012; final manuscript received June 3, 2013; published online xx xx, xxxx. Editor: Gerald E. Miller.

Carrie M. Nielson**Eric Orwoll**Oregon Health & Science University,
Portland, OR 97239**Doug Herthel**Alamo Pintado Equine Medical Center,
Los Olivos, CA 93441**Hal Kopeikin****Henry T. Y. Yang**Department of Physics,
University of California,
Santa Barbara, CA 93106**Joshua N. Farr****Louise McCready****Sundeep Khosla**Mayo Clinic,
Rochester, MN 55905**Adolfo Diez-Perez**Hospital del Mar-IMIM-Universitat
Autònoma and RETICEF,
Instituto Carlos III,
Barcelona, 08003 Spain**Paul K. Hansma**Department of Physics,
University of California,
Santa Barbara, CA 93106;
Active Life Technologies LLC,
Santa Barbara, CA 93101

Author Proof

6 1 Introduction

7 As people age, bone strength deteriorates and the skeleton
8 becomes more susceptible to fracture [1], which contributes to the
9 morbidity and mortality of osteoporosis. Bone strength is tradi-
10 tionally defined as the integration of bone mass and bone quality
11 [2]. Available techniques for clinical estimation of strength, how-
12 ever, are mainly based on bone mineral density assessments [3]
13 that are reliable but have modest sensitivity and specificity [3,4].
14 Furthermore, the ability of densitometry to predict the response to
15 a treatment is limited and only a small proportion of treatment
16 related fracture risk reduction is explained by bone mineral
17 density increases [5]. Advanced bone imaging and analysis tech-
18 nologies promise better assessment of bone strength [6] but rely
19 on potentially inaccurate assumptions about the tissue level
20 mechanical properties.

21 Therefore, there is a critical need to directly quantify bone's
22 ability to resist fracture. The most direct method to determine
23 fracture resistance would be to actually fracture a patient's bone
24 while measuring the difficulty of inducing the fractures. On a
25 large scale, this is clearly impractical; however, on a microscopic
26 scale, one can induce microfractures safely. Recently, a new tech-
27 nique, RPI [7–10], has been reported to quantify the ability of
28 bone to resist indentation in vivo and can also distinguish between
29 the bone of patients with and without fracture [7]. It does so by
30 inducing microfractures in the bone (Fig. 1) while measuring the
31 distance of penetration.




Fig. 1 Scanning electron microscope images of Osteoprobe indentations in the tibia of two different 83 year old female donors. These images display the microcracks created by the measurement to determine the BMS. The bone on the left (Sample A) appears to have fewer and shorter micro-cracks on the bone's surface, which resulted in a lower indentation distance and correspondingly a higher BMS of 89.8. Conversely, the bone on the right (Sample B) appears to have more micro-cracks, which resulted in a greater indentation distance and a lower BMS of 66.2. Thus, the bone with higher BMS is the bone that is more resistant to local damage from indentation.

32 There is both clinical and laboratory evidence suggesting that
33 mechanical properties of bone tissue may play a critical role in
34 bone strength [11–13]. One would expect these properties to play
35 a significant role in bone fracture risk; however, it is unclear what
36 mechanical properties are most important [14–17]. In addition,
37 currently available methods for estimates of these mechanical
38 properties require invasive bone sampling [18], making routine
39 clinical use unfeasible. The RPI instrument has the advantage of
40 directly measuring the bone's resistance to fracture, by creating
41 microfractures in a minimally invasive, measured procedure.

42 Results from a previous RPI instrument that distinguished frac-
43 ture patients from control patients [7] were acquired from an
44 instrument [9] that required a reference probe, a specially sharp-
45 ened hypodermic needle. After the initial clinical trials, several
46 improvements were made to the Reference Point Indentation
47 instrument to make the instrument easier to use, less invasive,
48 and more reproducible in a clinical setting, resulting in the
49 Osteoprobe® [19]. The Osteoprobe® is a handheld RPI instrument
50 that does not require a reference probe and is easier to use on
51 human patients and horses. Currently, the Osteoprobe® cannot be
52 used on small animal bones because it requires that the bone have
53 enough mass to avoid being simply pushed away rather than
54 indented during the impact. For these bones, a commercial RPI
55 instrument, such as the BioDent®, can be used.

56 This paper is a brief presentation of preliminary clinical data
57 obtained with this novel handheld RPI instrument on humans and
58 on horses. This article will focus on the application of the recently
59 introduced Osteoprobe® [19] to measure Bone Material Strength,
60 but as with the other RPI instruments previously described
61 [16–18], it is potentially useful for more general material charac-
62 terization. It provides a simple, handheld test that is useful in
63 cases where it is inconvenient to specially prepare samples for
64 conventional mechanical testing.

65 2 Osteoprobe® Operation and Measurements

66 **2.1 Instrument Operation.** The Osteoprobe® is designed to
67 create a microindentation in bone by applying a dynamic impact.
68 A 90 degree conical indenter with a diameter of approximately
69 380 μm is used. An initial preload on the sample of order 10 N is
70 applied to anchor the indenter into the bone and to ensure it has
71 pierced the periosteum. Once the preload force has been reached,
72 an impact will be initiated, which is the primary force used to
73 create the indentation. This impact generates a peak force of order
74 40 N and occurs in a fraction of a millisecond. After the impact
75 occurs, the operator will conclude the test or conduct further tests
76 in other locations (at least 2 mm away from previous site).

77 The primary measurement occurs during the impact cycle
78 where the indentation distance into the sample is measured. This
79 indentation distance cannot be measured absolutely, relative to
80 some external, rigid frame, because of (1) interference from soft
81 tissue on the surface of the bone, (2) the difficulty of keeping a
82 patient or horse absolutely still during measurement, and (3) the
83 bone itself cannot be held fixed relative to the external, rigid
84 frame because it is surrounded by soft tissue including muscles.
85 Consequentially, it is necessary to measure the indentation
86 distance relative to a reference point on the bone itself; thus RPI.
87 The Osteoprobe® eliminates the need for the physical reference
88 probe on the bone, while still maintaining the concept of using a
89 reference point. The reference point is the location where the
90 probe initially contacts the sample just before the impact is trig-
91 gered. The indentation distance increase from this reference point
92 results from the impact is measured with a custom strain gauge
93 mechanism. This reference point is suitable because the inertia of
94 the body of the instrument keeps it adequately fixed in space dur-
95 ing the short duration of the impact. Thus, the distance measured
96 with the strain gauge is the same as the distance that the probe fur-
97 ther indents into the sample from the reference point. The elimina-
98 tion of the reference probe has the advantage of simplicity and of

removing the possibility of soft tissue buildup and friction 99
between the test probe and the reference probe as in other RPI 100
Devices [7–10]. Further detail of the instrument operation has 101
been reported previously by Bridges et al. [19]. 102

2.2 Bone Material Strength Measurement. The measure- 103
ment taken by the Osteoprobe® is a new parameter, called Bone 104
Material Strength (BMS) [19], which quantifies how well a bone 105
resists microindentation. Bone Material Strength is defined as 100 106
times the ratio of the indentation distance from the impact into a 107
calibration material, PMMA (poly (methyl-methacrylate), divided 108
by the indentation distance from the impact into the bone. As the 109
probe indents, it induces microfractures. The more easily the bone 110
material is fractured, the deeper the probe indents and thus the 111
lower the BMS. 112

BMS determined from impact microindentation testing has 113
been shown to discriminate patients with and without hip fractures 114
in a case-control study [20]. As a result of these findings, it can 115
be inferred that BMS is a measure of the contribution of bone 116
material properties to whole bone fracture risk. 117

2.3 Measurement Correlations. Bone Material Strength, 118
measured with the Osteoprobe®, was correlated with the Bio- 119
Dent® [7–10] and a standard Vickers hardness test. Cadaver 120
samples of cortical bone were excised from the mid diaphysis of 121
the tibia from two 83 year old female donors. One donor had no 122
history of bone disease (Sample A) and the other donor had Type 123
II Diabetes (Sample B). Ten indentation tests were conducted 124
with each RPI instrument and three Vickers hardness measure- 125
ments were obtained from each sample. The results are shown in 126
Table 1. The results show a correlation between all three mechani- 127
cal tests with the same trend. We note, however, that the Vickers 128
hardness measurements are only practical in bone samples from 129
which the soft tissue has been removed, but not in living animals 130
or patients because Vickers hardness measurements depend on 131
imaging the indentation, which would be very difficult even in 132
cases where the bone were surgically exposed. 133

Figure 1 shows two Scanning Electron Microscope (SEM) 134
images of an indentation into each of the test samples. Since the 135
SEM image is only of the bone surface, we are unable to quantify 136
fractures completely as it is unknown how the fractures propagate 137
below the surface; however, it appears that more fractures were 138
created on Sample B, which had a BMS of 66.2, compared to 139
Sample A, which appears to resist microfractures and has a BMS 140
of 89.8. These results show a correlation between BMS and the 141
local microscopic damage that contributes to a larger indentation. 142

3 Human Testing 143

3.1 Clinical Tests of Living Humans In Vivo. Human clinical 144
trials were performed in Barcelona, Spain, and in Oregon and 145
at the Mayo Clinic in the United States. The trials in Barcelona 146
involve elderly women over the age of 60 with no history of 147

Table 1 Results obtained by three different mechanical testers on cortical bone samples from the tibia of two different 83 year old female donors. All instruments show the trend of Sample A being indented easier than Sample B. Note both the BMS and Vickers Hardness have a positive correlation while the correlation with Total Indentation Distance (TID) is negative. This is due to BMS and Vickers Hardness being inversely related to indentation distance, while the TID does not have this inverse relationship to indentation distance.

Sample ID	Osteoprobe (BMS) N = 10	BioDent (TID) N = 10	Vickers (HV45/30) N = 3
A	90.37 \pm 4.30	98.60 \pm 4.39	26.68 \pm 2.38
B	73.75 \pm 13.24	106.33 \pm 5.99	16.44 \pm 1.53




Fig. 2 In vivo testing on a human patient with the calibration phantom (PMMA) test results. The spread of values for the patient, compared to the PMMA Phantom, is larger due to the natural heterogeneity of the bone. This is why at least five tests are conducted in vivo on humans: to reduce the error of the mean below the value that typically separates one patient from another.




Fig. 3 BMS values of ex vivo human samples comparing through tissue tests to tests performed on exposed bone. The data suggests that there is no significant difference in BMS values between these two methods of indentation ($p > 0.25$), which is vital because it demonstrates the Osteoprobe[®]'s consistency between through tissue and exposed bone tests, typical of in vivo and ex vivo testing, respectively.

148 receiving drug treatment for bone-related conditions. The trials in
 149 Oregon involved elderly men. Patients were conscious with only
 150 local anesthesia used at the measurement site and no serious comp-
 151 lications have been reported. Currently the range in BMS seen in
 152 the Barcelona study is 56 to 94 with a mean of 79 and a standard
 153 deviation of 8. The range of BMS seen in the Oregon study is 69
 154 to 94 with a mean of 85 and a standard deviation of 9. The similar-
 155 ity of the ranges and standard deviations obtained from these two
 156 independent clinical trials reveal that the results obtained from the
 157 Osteoprobe[®] can be highly consistent between different popula-
 158 tions of test subjects. In addition, the small variability in measured
 159 BMS from user to user highlights its potential wide-spread clinical
 160 applicability in assaying fracture risk.

161 It is important to note that bone is a heterogeneous material;
 162 therefore the measurements on a single patient have a larger
 163 standard deviation than the measurements on the calibration phan-
 164 tom, poly(methyl methacrylate) (PMMA), which is much more
 165 homogeneous (see Fig. 2). This larger standard deviation is not
 166 due to the instrument, but rather the natural heterogeneity of bone.
 167 For this reason, each patient had at least five measurements taken
 168 in one general location. The probe only pierces the skin once, and
 169 then is moved incrementally for each of the five measurements
 170 around the insertion site, with a separation of at least 2 mm
 171 between measurement sites.

172 At the Mayo Clinic, a recent test was conducted to investigate
 173 the reproducibility of the Osteoprobe[®] measurements. The opera-
 174 tor performed ten measurements on a patient, put down the instru-
 175 ment, paused, and then repeated ten additional measurements. For
 176 the initial eight patients, the coefficient of determination (R^2) was
 177 0.90 when all ten measurements were used; however, it fell to
 178 0.73 if only the first five measurements were used. These results
 179 suggest that ten (or more) measurements should be performed on
 180 each patient in future tests. The majority of the time involved in
 181 the procedure is spent preparing the patient; therefore performing
 182 ten measurements rather than five measurements has a small
 183 impact on the duration of the test procedure as each measurement
 184 takes only a few seconds.

185 **3.2 Laboratory Tests of Human Donor Samples Through**
 186 **Skin Versus on Bare Bone.** An experiment was conducted to
 187 identify potential inconsistencies between data collected from
 188 tests performed on exposed bone compared to bone tested through
 189 intact tissue overlaying bone. This is a critical investigation
 190 because it is a primary difference between clinical in vivo tests

and ex vivo tests, typical of a laboratory setting. Two cadaveric 191
 samples from the medial section of the right tibia from a female 192
 donor (age 83) from the University of California Irvine Health 193
 Affairs Willied Body Program were tested while submerged in 194
 Hank's buffered saline solution and clamped in place by a 195
 mechanical vice. One sample was tested through the local soft 196
 tissue, whereas the second was tested after removing all soft 197
 tissue, including scraping off the surrounding periosteum. When 198
 testing through the soft tissue, the probe was inserted through the 199
 skin and periosteum until it was resting on the bone surface. Once 200
 on the surface, a measurement was taken. Each sample was tested 201
 ten times and the average values of BMS were compared (Fig. 3). 202
 This test confirmed that there is not a significant discrepancy in 203
 BMS values between testing on exposed bone compared to testing 204
 with the presence of overlaying tissue ($p > 0.25$). These findings 205
 are consistent with numerous other previous tests conducted dur- 206
 ing instrument development to optimize the trigger force and 207
 impact force with the goal of having the same reading for both 208
 through-tissue and bare-bone parallel measurements. These results 209
 verify that this novel instrument is capable of penetrating both the 210
 bone's soft tissue and the periosteum, typically the most difficult 211
 soft tissue to penetrate between the skin and the bone, which is 212
 critical for in vivo use. 213

4 Testing Horses 214

4.1 Clinical Testing of a Standing Horse In Vivo. Bone 215
 fracture is also a serious problem for horses, especially thorough- 216
 bred race horses. There is therefore a need to develop tools for the 217
 minimally invasive assay of fracture risk in these animals. In gen- 218
 eral, it is preferable if measurements can be made on standing 219
 horses, with the process being much faster and less invasive. 220
 Initial attempts using the earlier version of the RPI instrument on 221
 horses yielded little success. The biggest problem was irreproduci- 222
 bility caused by horse movement during the extended (10 s) mea- 223
 surement time required by the previous instrument. The solution 224
 to this problem is the drastically decreased 1 ms measurement 225
 time of the present instrument. Another related problem was that 226
 it was necessary to affix an appliance to hold the previous RPI 227
 onto the horse's leg, again because of the prolonged 10 s measure- 228
 ment time. The horse would regard this appliance as an irritation, 229
 treating it as something which should be removed by kicking, 230
 obviously limiting its usefulness. These problems were eliminated 231
 with the present instrument which is capable of very rapid testing 232
 (less than 1 ms) while being handheld (Fig. 4). Although the 233



Fig. 4 Bone fracture is a serious problem for horses, especially thoroughbred race horses. Here one of us (DH) at Alamo Pintado stables measures the Bone Material Strength of a young, lame thoroughbred horse. He and (KH) each measured both legs and obtained BMS of 80 ± 13 .

234 horses required a sedative and local anesthesia at the measurement
235 site, they were conscious. Thus measurements were obtained suc-
236 cessfully on standing horses.

237 **4.2 Clinical Trial on Anesthetized Horse Through Skin**
238 **Versus on Bare Bone.** To verify that the instrument can penetrate
239 horse's periosteum and obtain similar results through tissue and
240 on bare bone, an experiment was conducted on a horse that was
241 previously scheduled to be euthanized at Purdue University. The
242 horse was tested before death through tissue, after death through
243 tissue, and after death on bare bone. The most difficult step in the
244 procedure is penetrating the skin, as it is very tough and a sharp
245 probe is necessary. However, once the probe was on the bone sur-
246 face it could be moved easily to find a relatively flat surface of the
247 bone that has not been indented without the need to remove the
248 probe between indentations. The results showed that there was
249 only a small difference between the through tissue (mean BMS of
250 88) and bare bone test (mean BMS of 84). This validates that the
251 Osteoprobe[®] can penetrate the skin and periosteum for in vivo
252 horse testing and still gives reliable results on the bone itself.

253 In general, the experience of measuring standing horses was
254 similar to the experience of measuring humans. In both cases,
255 only local anesthesia was used at the measurement site and, for
256 the horses, a sedative. In both cases, the patient was awake. For
257 the case of an unconscious, anesthetized horse, due to euthanasia,
258 it was practical to take many more measurements than on a fully
259 conscious human or horse. From these tests, it can be seen that
260 there is somewhat more scatter in the data on horses compared to
261 data on people. Based on an ANOVA analysis by Morton Brown
262 [9], we had converged on five as an adequate number of tests for a
263 human patient with the conventional RPI instrument. As discussed
264 above, ten tests is better than five with the Osteoprobe[®]. Since the
265 scatter is more for the horses, a new ANOVA analysis will be nec-
266 essary to determine the optimal number of tests for a horse
267 patient. Based on these current findings, it would be conservative
268 and safe to perform five measurements in each of the four skin
269 punctures for a total of 20 measurements per horse.

5 Discussion

270 The Osteoprobe[®] is an easy-to-use instrument which provides
271 reproducible measurements of the material strength of bone in not
272 only laboratory samples, but also in clinical trials on humans and
273 horses. A novel aspect of this instrument is the method by which
274 it directly measures the indentation resistance in bone, while
275 actually creating fractures. We presented clinical studies on
276 humans that provided reasonable and consistent values. The
277 Osteoprobe[®] has been shown to successfully obtain BMS mea-
278 surements through the soft tissue of both horses and humans
279 in vivo. The instrument is able to pierce the soft tissue and perios-
280 teum without the need of a reference probe to push the tissue
281 aside. This is an important advancement because it provides for a
282 less invasive procedure compared to previous RPI instruments
283 and does not require extensive training, making the Osteoprobe[®] a
284 very simple instrument to operate. Further tests will be needed to
285 determine the significance of the measured parameters in animal
286 and human subjects, but initial tests presented here are quite
287 positive.
288

Acknowledgment

289 We thank the Fondo de Investigaciones Sanitarias (PI07/90912)
290 and the RETICEF (RD06/0013/1009) of the Instituto Carlos III,
291 Spanish Ministry of Science and Technology, the Mayo Center
292 for Translational Science Activities (UL1 RR024150), and the
293 NIH RO1 GM 065354 for support of this work. The authors wish
294 to thank individuals who donate their bodies and tissues for the
295 advancement of education and research. The measurements
296 reported here were done with prototype instruments, but Active
297 Life Scientific, Inc. may, in the future, produce a commercial
298 version of this instrument if there is demand for it. Four of the
299 authors, P.H., D.B., J.C., and A.P., are members of Active Life
300 Scientific.
301

302 Laboratory Study design: CR, DB, PKH. Laboratory Study con-
303 duct: CR, DB, SR, HB, PKH. Barcelona Study design: ADP and
304 RGF. Barcelona Study conduct: RGF, ADP, XN, ET, LM. Purdue
305 Study design: TL, SC. Purdue Study conduct: TS, AS, CS, TL.
306 Oregon Study design: EO. Oregon Study conduct: CN, EO.
307 Alamo Pintado Study design and conduct: DH. Mayo Study
308 design: SK. Mayo Study conduct: JNF, LM, SK. SEM imaging:
309 JW. Statistics: HK. Assisted in the organization of studies: DB,
310 AP, JC. Writing and Drafting manuscript: CR, DB, PKH. All
311 authors approve final version of manuscript.

References

- [1] Eitinger, M. P., 2003, "Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly," *Arch. Intern. Med.*, **163**, pp. 2237–2246. 312
- [2] NIH Consensus Development Panel, 2001, "Osteoporosis Prevention, Diagnosis, and Therapy," *J. Am. Med. Assoc.*, **285**, pp. 785–795. 313
- [3] Rivadeneira, F., Zillikens, M. C., Laet, C. E. D., Hofman, A., Uitterlinden, A. G., Beck, T. J., and Pols, H. A., 2007, "Femoral Neck BMD is a Strong Predictor of Hip Fracture Susceptibility in Elderly Men and Women Because it Detects Cortical Bone Instability," *J. Bone Miner. Res.*, **22**, pp. 1781–1790. 314
- [4] Yang, L., Peel, N., Clowes, J. A., McCloskey E. V., and Eastell, R., 2009, "Use of DXA-Based Structural Engineering Models of the Proximal Femur to Discriminate Hip Fracture," *J. Bone Miner. Res.*, **24**, pp. 33–42. 315
- [5] Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., and Black, D. M., 2002, "Improvement in Spine Bone Density and Reduction in Risk of Vertebral Fractures During Treatment With Antiresorptive Drugs," *Am. J. Med.*, **112**, pp. 281–289. 316
- [6] Boutroy, S., Rietbergen, B. V., Sornay-Rendu, E., Munoz, F., Bouxsein, M. L., and Delmas, P. D., 2008, "Finite Element Analysis Based on In Vivo HR-pQCT Images of the Distal Radius is Associated With Wrist Fracture in Postmenopausal Women," *J. Bone Miner. Res.*, **23**, pp. 392–399. 317
- [7] Diez-Perez, A., Guerri, R., Noguez, X., Caceres, E., Pena, M. J., Mellibovsky, L., Randall, C., Bridges, D., Weaver, J. C., Proctor, A., Brimer, D., Koester, K. J., Ritchie, R. O., and Hansma, P. K., 2010, "Microindentation for In Vivo Measurement of Bone Tissue Mechanical Properties in Humans," *J. Bone Miner. Res.*, **25**, pp. 1877–1885. 318
- [8] Hansma, P., Yu, H., Schultz, D., Rodriguez, A., Yurtsev, E. A., Orr, J., Tang, S., Miller, J., Wallace, J., Zok, F., Li, C., Souza, R., Proctor, A., 319

- 331 Brimer, D., Nogues-Solan, X., Mellibovsky, L., Pena, M. J., Diez-Ferrer, O.,
 332 Mathews, P., Randall, C., Kuo, A., Chen, C., Peters, M., Kohn, D., Buck-
 333 ley, J., Li, X., Pruitt, L., Diez-Perez, A., Alliston, T., Weaver, V., and
 334 Lotz, J., 2009, "Tissue Diagnostic Instrument," *Rev. Sci. Instrum.*, **80**, p.
 335 054303.
- [9] Hansma, P., Turner, P., Drake, B., Yurtsev, E., Proctor, A., Mathews, P.,
 336 Lulejian, J., Randall, C., Adams, J., Jungmann, R., Garza-de-Leon, F., Fantner,
 337 G., Mkrtychyan, H., Pontin, M., Weaver, A., Brown, M. B., Sahar, N., Rossello,
 338 R., and Kohn, D., 2008, "The Bone Diagnostic Instrument II: Indentation Dis-
 339 tance Increase," *Rev. Sci. Instrum.*, **79**, p. 064303.
- [10] Hansma, P. K., Turner, P. J., and Fantner, G. E., 2006, "Bone Diagnostic
 340 Instrument," *Rev. Sci. Instrum.*, **77**, p. 075105.
- [11] Chavassieux, P., Seeman, E., and Delmas, P. D., 2007, "Insights into Material
 341 and Structural Basis of Bone Fragility from Diseases Associated with Fractures:
 342 How Determinants of the Biomechanical Properties of Bone are Compromised
 343 by Disease," *Endocr. Rev.*, **28**, pp. 151–164.
- [12] Vashishth, D., 2005, "Age-Dependent Biomechanical Modifications in Bone,"
 344 *Crit. Rev. Eukar. Gene.*, **15**, pp. 343–357.
- [13] Currey, J. D., 1979, "Changes in the Impact Energy Absorption of Bone With
 345 Age," *J. Biomech.*, **12**, pp. 459–469.
- [14] Currey, J., 2004, "Incompatible Mechanical Properties in Compact Bone,"
 346 *J. Theor. Biol.*, **231**, pp. 569–580.
- [15] Turner, C. H., 2002, "Biomechanics of Bone: Determinants of Skeletal Fragility
 347 and Bone Quality," *Osteop. Int.*, **13**, pp. 97–104.
- [16] Bouxsein, M. L., 2003, "Bone Quality: Where Do We Go From Here?," *Osteop.*
 348 *Int.*, **14**, pp. S118–S127.
- [17] Jepsen, K. J., 2003, "The Aging Cortex: To Crack or not to Crack," *Osteop.*
 349 *Int.*, **14**, pp. S57–S62.
- [18] Seeman, E., and Delmas, P. D., 2006, "Bone Quality—The Material and Struc-
 350 tural Basis of Bone Strength and Fragility," *New Engl. J. Med.*, **354**, pp.
 351 2250–2261.
- [19] Bridges, D., Randall, C., and Hansma, P., 2012, "A New Device for Performing
 352 Reference Point Indentation Without a Reference Probe," *Rev. Sci. Instrum.*,
 353 **83**, p. 044301.
- [20] Fernandez, R., Diez-Perez, A., Nogues, X., Prieto-alhambra, D., Mellibovsky,
 354 L., Bridges D., Randall, C., and Hansma, P., 2011, "Validation of a Novel
 355 Microindenter for Bone Material Strength Measurement," American Society for
 356 Bone and Mineral Research 2011 Annual Meeting, [http://www.asbmr.org/
 357 Meetings/AnnualMeeting/AbstractDetail.aspx?aid=cb0278aa-14cf-47e2-84be-
 358 8bf2a7e7896e](http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=cb0278aa-14cf-47e2-84be-8bf2a7e7896e)

Author Proof